Hanchard M
Orphanet J Rare Dis. 2025; 20(1):107.
PMID: 40055799
PMC: 11887186.
DOI: 10.1186/s13023-025-03634-2.
Blonda A, Denier Y, Huys I, Kawalec P, Simoens S
Front Pharmacol. 2022; 13:902150.
PMID: 35928274
PMC: 9343828.
DOI: 10.3389/fphar.2022.902150.
Caetano R, Correa M, Villardi P, Almeida Rodrigues P, Osorio-de-Castro C
PLoS One. 2021; 16(3):e0247853.
PMID: 33667235
PMC: 7935269.
DOI: 10.1371/journal.pone.0247853.
Klingelhofer D, Braun M, Seeger-Zybok R, Quarcoo D, Bruggmann D, Groneberg D
Mol Genet Genomic Med. 2020; 8(9):e1163.
PMID: 32031327
PMC: 7507033.
DOI: 10.1002/mgg3.1163.
Goble J, Ung B, van Boemmel-Wegmann S, Navarro R, Parece A
J Manag Care Spec Pharm. 2017; 23(10):1042-1052.
PMID: 28944728
PMC: 10398123.
DOI: 10.18553/jmcp.2017.23.10.1042.
Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?.
Adkins E, Nicholson L, Floyd D, Ratcliffe M, Chevrou-Severac H
Clinicoecon Outcomes Res. 2017; 9:327-342.
PMID: 28652787
PMC: 5473500.
DOI: 10.2147/CEOR.S134230.
Determinants of orphan drugs prices in France: a regression analysis.
Korchagina D, Millier A, Vataire A, Aballea S, Falissard B, Toumi M
Orphanet J Rare Dis. 2017; 12(1):75.
PMID: 28427466
PMC: 5399414.
DOI: 10.1186/s13023-016-0561-5.
Compassionate use of orphan drugs.
Hyry H, Manuel J, Cox T, Roos J
Orphanet J Rare Dis. 2015; 10:100.
PMID: 26292942
PMC: 4546220.
DOI: 10.1186/s13023-015-0306-x.
Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.
Gutierrez L, Patris J, Hutchings A, Cowell W
Orphanet J Rare Dis. 2015; 10:53.
PMID: 25935555
PMC: 4433088.
DOI: 10.1186/s13023-015-0269-y.
Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years.
Tomanin R, Zanetti A, DAvanzo F, Rampazzo A, Gasparotto N, Parini R
Orphanet J Rare Dis. 2014; 9:129.
PMID: 25231261
PMC: 4180060.
DOI: 10.1186/s13023-014-0129-1.
Shining a light in the black box of orphan drug pricing.
Picavet E, Morel T, Cassiman D, Simoens S
Orphanet J Rare Dis. 2014; 9:62.
PMID: 24767472
PMC: 4018963.
DOI: 10.1186/1750-1172-9-62.
Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.
Hutchings A, Schey C, Dutton R, Achana F, Antonov K
Orphanet J Rare Dis. 2014; 9:22.
PMID: 24524281
PMC: 3930763.
DOI: 10.1186/1750-1172-9-22.
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.
Morel T, Arickx F, Befrits G, Siviero P, van der Meijden C, Xoxi E
Orphanet J Rare Dis. 2013; 8:198.
PMID: 24365263
PMC: 3882782.
DOI: 10.1186/1750-1172-8-198.
The legal imperative for treating rare disorders.
Hyry H, Roos J, Manuel J, Cox T
Orphanet J Rare Dis. 2013; 8:135.
PMID: 24010951
PMC: 4016581.
DOI: 10.1186/1750-1172-8-135.
Cost-effectiveness of enzyme replacement therapy for Fabry disease.
Rombach S, Hollak C, Linthorst G, Dijkgraaf M
Orphanet J Rare Dis. 2013; 8:29.
PMID: 23421808
PMC: 3598841.
DOI: 10.1186/1750-1172-8-29.
Unintended effects of orphan product designation for rare neurological diseases.
Murphy S, Puwanant A, Griggs R
Ann Neurol. 2012; 72(4):481-90.
PMID: 23109143
PMC: 3490440.
DOI: 10.1002/ana.23672.
Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?.
Hughes-Wilson W, Palma A, Schuurman A, Simoens S
Orphanet J Rare Dis. 2012; 7:74.
PMID: 23013790
PMC: 3582462.
DOI: 10.1186/1750-1172-7-74.
Imiglucerase in the treatment of Gaucher disease: a history and perspective.
Deegan P, Cox T
Drug Des Devel Ther. 2012; 6:81-106.
PMID: 22563238
PMC: 3340106.
DOI: 10.2147/DDDT.S14395.
The prevalence and cost of unapproved uses of top-selling orphan drugs.
Kesselheim A, Myers J, Solomon D, Winkelmayer W, Levin R, Avorn J
PLoS One. 2012; 7(2):e31894.
PMID: 22363762
PMC: 3283698.
DOI: 10.1371/journal.pone.0031894.
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?.
Brabers A, Moors E, van Weely S, de Vrueh R
Orphanet J Rare Dis. 2011; 6:59.
PMID: 21892964
PMC: 3185263.
DOI: 10.1186/1750-1172-6-59.
